Carboxyamidotriazole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Carboxyamidotriazole
Accession Number
DB11960
Type
Small Molecule
Groups
Investigational
Description

Carboxyamidotriazole has been used in trials studying the treatment of Lymphoma, Lung Cancer, Breast Cancer, Kidney Cancer, and Ovarian Cancer, among others.

Structure
Thumb
Synonyms
  • CAI
External IDs
L 651582 / NSC-609974
Categories
UNII
6ST3ZF52WB
CAS number
99519-84-3
Weight
Average: 424.67
Monoisotopic: 423.0056577
Chemical Formula
C17H12Cl3N5O2
InChI Key
WNRZHQBJSXRYJK-UHFFFAOYSA-N
InChI
InChI=1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)
IUPAC Name
5-amino-1-{[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl}-1H-1,2,3-triazole-4-carboxamide
SMILES
NC(=O)C1=C(N)N(CC2=CC(Cl)=C(C(=O)C3=CC=C(Cl)C=C3)C(Cl)=C2)N=N1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Carboxyamidotriazole.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Carboxyamidotriazole.Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Carboxyamidotriazole.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Carboxyamidotriazole.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Carboxyamidotriazole.Approved, Investigational
AmobarbitalThe metabolism of Carboxyamidotriazole can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Carboxyamidotriazole.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carboxyamidotriazole.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Carboxyamidotriazole.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Carboxyamidotriazole.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Atosiban.Approved, Investigational
Atracurium besylateCarboxyamidotriazole may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Carboxyamidotriazole.Experimental
BarbexacloneThe metabolism of Carboxyamidotriazole can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Carboxyamidotriazole can be increased when combined with Barbital.Illicit
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Carboxyamidotriazole.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Carboxyamidotriazole.Approved, Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Carboxyamidotriazole.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Carboxyamidotriazole.Experimental
BucindololBucindolol may increase the hypotensive activities of Carboxyamidotriazole.Investigational
BunazosinBunazosin may increase the hypotensive activities of Carboxyamidotriazole.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Carboxyamidotriazole.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Carboxyamidotriazole.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carboxyamidotriazole.Approved
CalciumThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium.Approved, Nutraceutical
Calcium AcetateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Carbonate.Approved
Calcium CitrateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Carboxyamidotriazole.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Carboxyamidotriazole.Experimental
CarbomycinThe metabolism of Carboxyamidotriazole can be decreased when combined with Carbomycin.Vet Approved
CarvedilolCarvedilol may increase the hypotensive activities of Carboxyamidotriazole.Approved, Investigational
CaseinThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Carboxyamidotriazole.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Carboxyamidotriazole.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Carboxyamidotriazole.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Carboxyamidotriazole.Approved, Investigational
CimetidineThe serum concentration of Carboxyamidotriazole can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Carboxyamidotriazole can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Carboxyamidotriazole.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Carboxyamidotriazole.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Carboxyamidotriazole.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Carboxyamidotriazole.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Carboxyamidotriazole.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Carboxyamidotriazole.Experimental
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Carboxyamidotriazole.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Carboxyamidotriazole.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Carboxyamidotriazole.Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Carboxyamidotriazole.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Carboxyamidotriazole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carboxyamidotriazole.Approved, Investigational
DoxazosinDoxazosin may increase the hypotensive activities of Carboxyamidotriazole.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Carboxyamidotriazole.Approved
EfavirenzThe serum concentration of Carboxyamidotriazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Carboxyamidotriazole.Approved
ErythromycinThe metabolism of Carboxyamidotriazole can be decreased when combined with Erythromycin.Approved, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Carboxyamidotriazole.Experimental
FluconazoleThe serum concentration of Carboxyamidotriazole can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Carboxyamidotriazole.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Carboxyamidotriazole.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Carboxyamidotriazole.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Carboxyamidotriazole.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Carboxyamidotriazole.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Carboxyamidotriazole.Approved, Vet Approved
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Carboxyamidotriazole.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Carboxyamidotriazole.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Carboxyamidotriazole.Approved, Investigational
HexobarbitalThe metabolism of Carboxyamidotriazole can be increased when combined with Hexobarbital.Approved
IndoraminIndoramin may increase the hypotensive activities of Carboxyamidotriazole.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Carboxyamidotriazole.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Carboxyamidotriazole.Approved, Investigational
JosamycinThe metabolism of Carboxyamidotriazole can be decreased when combined with Josamycin.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Carboxyamidotriazole.Approved, Investigational
KitasamycinThe metabolism of Carboxyamidotriazole can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Carboxyamidotriazole.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Carboxyamidotriazole.Experimental
LovastatinThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Lovastatin.Approved, Investigational
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Magnesium Sulfate.Approved, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Carboxyamidotriazole.Experimental
MethohexitalThe metabolism of Carboxyamidotriazole can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Carboxyamidotriazole can be increased when combined with Methylphenobarbital.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Carboxyamidotriazole.Experimental
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Carboxyamidotriazole.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Carboxyamidotriazole.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Carboxyamidotriazole.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Carboxyamidotriazole.Approved
MivacuriumCarboxyamidotriazole may increase the neuromuscular blocking activities of Mivacurium.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Carboxyamidotriazole.Vet Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Carboxyamidotriazole.Experimental
NafcillinThe metabolism of Carboxyamidotriazole can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Carboxyamidotriazole.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Carboxyamidotriazole.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Carboxyamidotriazole.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Carboxyamidotriazole.Investigational
NitroprussideCarboxyamidotriazole may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Carboxyamidotriazole.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Carboxyamidotriazole.Approved, Vet Approved
OleandomycinThe metabolism of Carboxyamidotriazole can be decreased when combined with Oleandomycin.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Carboxyamidotriazole.Experimental, Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Carboxyamidotriazole.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Carboxyamidotriazole.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Carboxyamidotriazole.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carboxyamidotriazole.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Carboxyamidotriazole.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Carboxyamidotriazole.Approved
PentobarbitalThe metabolism of Carboxyamidotriazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Carboxyamidotriazole.Experimental
PhenobarbitalThe metabolism of Carboxyamidotriazole can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Carboxyamidotriazole.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Carboxyamidotriazole.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Carboxyamidotriazole.Approved
PrimidoneThe metabolism of Carboxyamidotriazole can be increased when combined with Primidone.Approved, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Carboxyamidotriazole.Experimental
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Carboxyamidotriazole.Experimental
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Carboxyamidotriazole.Experimental
RapacuroniumCarboxyamidotriazole may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RifabutinThe serum concentration of Carboxyamidotriazole can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Carboxyamidotriazole can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Carboxyamidotriazole can be decreased when it is combined with Rifapentine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Rosuvastatin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Carboxyamidotriazole.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Carboxyamidotriazole.Approved, Vet Approved
SecobarbitalThe metabolism of Carboxyamidotriazole can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Carboxyamidotriazole.Approved
SilodosinSilodosin may increase the hypotensive activities of Carboxyamidotriazole.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Carboxyamidotriazole.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Carboxyamidotriazole.Approved, Investigational
SolithromycinThe metabolism of Carboxyamidotriazole can be decreased when combined with Solithromycin.Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Carboxyamidotriazole.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Carboxyamidotriazole.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Carboxyamidotriazole.Approved
TelithromycinThe metabolism of Carboxyamidotriazole can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may increase the hypotensive activities of Carboxyamidotriazole.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Carboxyamidotriazole.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Carboxyamidotriazole.Approved
ThiamylalThe metabolism of Carboxyamidotriazole can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Carboxyamidotriazole can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Carboxyamidotriazole.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Carboxyamidotriazole.Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Carboxyamidotriazole.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Carboxyamidotriazole.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Carboxyamidotriazole.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Carboxyamidotriazole.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Carboxyamidotriazole.Approved, Investigational
TylosinThe metabolism of Carboxyamidotriazole can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Ubidecarenone.Approved, Experimental
UrapidilUrapidil may increase the hypotensive activities of Carboxyamidotriazole.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Carboxyamidotriazole.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
108144
PubChem Substance
347828284
ChemSpider
97232
BindingDB
97191
ChEMBL
CHEMBL95431

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Breast / Cancer, Ovarian / Lung Cancers / Malignant Lymphomas / Melanoma (Skin) / Renal Cancers / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentRecurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
2CompletedTreatmentRenal Cancers1
3CompletedTreatmentStage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00318 mg/mLALOGPS
logP3.71ALOGPS
logP4.16ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)13.13ChemAxon
pKa (Strongest Basic)0.69ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area116.89 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity115.58 m3·mol-1ChemAxon
Polarizability39.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzophenones
Direct Parent
Benzophenones
Alternative Parents
Aryl-phenylketones / Diphenylmethanes / 2-heteroaryl carboxamides / Dichlorobenzenes / Benzoyl derivatives / Aryl chlorides / Vinylogous halides / Vinylogous amides / Triazoles / Heteroaromatic compounds
show 8 more
Substituents
Benzophenone / Aryl-phenylketone / Diphenylmethane / 2-heteroaryl carboxamide / Benzoyl / Aryl ketone / 1,3-dichlorobenzene / Halobenzene / Chlorobenzene / Aryl chloride
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:05 / Updated on November 09, 2017 05:00